MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT PHOEBUS is…
Categorie
2023
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference Poster 1 presents Early Access…
November 2, 2023
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to…
October 31, 2023
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with…
October 26, 2023
MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France, October 9,…
October 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
October 6, 2023
MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Two posters…
September 27, 2023
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update The ARES study on MaaT013 reached the…
September 26, 2023
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.